We then compared the expression of promising DCIS risk biomarkers (Ki-67, p53 and p16) among the different DCIS subgroups, classified based on adjacent TDLU and IDC, to examine whether an “aggressive” DCIS subpopulation existed. This evidence concerns the gene MKI67 and ductal breast carcinoma in situ.